All
Opdivo Plus Cabometyx Safe, Effective in Advanced Renal Cell Carcinoma
Opdivo plus Cabometyx resulted in a significant progression and survival benefits compared with Sutent in the first-line treatment of patients with advanced renal cell carcinoma.
Cabometyx Combo Maintains Progression-Free Survival Benefit in Advanced RCC
Final results were consistent with previously conducted research in patients with advanced renal cell carcinoma treated with Cabometyx, Opdivo and Yervoy.
Antitumor Activity Elicited in ccRCC Following Lenvima/Welireg Treatment
Among patients with clear cell renal cell carcinoma, improved responses were observed with Lenvima plus Welireg versus Keytruda plus Lenvima.
FDA-Approved Fotivda Dose More Effective Than Reduced Dose in RCC
Researchers showed that 1.34 mg of Fotivda provided decreased tumor size and may be more tolerable than an 0.89-mg dose among patients with renal cell carcinoma.
Bavencio Has Efficacy in The Real-World Treatment of Urothelial Cancer
Following treatment with Bavencio, patients with urothelial cancer lived for 17 months and their cancer remained stable for nine months.
Padcev Significantly Improves OS in Real-World Urothelial Carcinoma
Among patients in the real world with unresectable or metastatic urothelial carcinoma, Padcev significantly improved overall survival outcomes.
Understanding How One Must Interpret PSA Levels in Prostate Cancer
Dr. Barry W. Goy explains how to interpret PSA levels after prostate cancer treatment and how to manage recurrence based on disease progression.
Padcev Plus Keytruda Shows Promise for Upper Tract Urothelial Carcinoma Lesions
Results from a small retrospective analysis of patients with upper tract urothelial carcinoma lesions were shared at the 2025 ASCO Genitourinary Cancers Symposium.
High Omega-3 Diet With Fish Oil Reduces Ki-67 Index in Prostate Cancer
Among patients with prostate cancer, a high omega-3, low-omega-6 diet with fish oil led to a Ki-67 index decrease.
Neuropathy, Rash, Hyperglycemia Linked to PFS in Urothelial Carcinoma
Neuropathy, skin rash, and hyperglycemia following enfortumab vedotin treatment were associated with improved PFS in metastatic urothelial carcinoma.
Padcev May Be Safe in Older Patients With Bladder Cancer
Results also show that reducing the Padcev dose at treatment initiation may benefit older patients with urothelial carcinoma, a type of bladder cancer.
Are We at Risk of Losing Our Breast Cancer Community?
I found community after my metastatic breast cancer diagnosis, but recent discord in cancer support groups makes me fear we're losing these vital connections.
Estrogen Patches with ARPIs Found to Be Safe, Effective in Prostate Cancer
Responses were similar among patients with estrogen patches and ARPIs compared to luteinizing hormone releasing hormone analogues and ARPIs among patients with metastatic prostate cancer.
Linvoseltamab BLA Resubmission Accepted by FDA for Review
The FDA accepted Regeneron’s BLA resubmission for linvoseltamab in relapsed or refractory multiple myeloma, with a decision expected by July 10, 2025.
Nubeqa Plus ADT Effective in mHSPC Regardless of Disease Volume
Nubeqa plus ADT improved rPFS in mHSPC regardless of disease volume, reducing the risk of radiological progression or death by 46%, per ARANOTE data.
Patients With Prostate Cancer Experience Temporary Urinary Function Decline After CIRT
Although carbon ion radiation led to a decline in urinary function among patients with prostate cancer, function returned to normal after three months.
An Expert Explains Updated Data For Patients With GU Cancers
Dr. Guru P Sonpavde discusses updated data from studies like EV-302 and CheckMate 274 for patients with urothelial cancer at the 2025 ASCO GU meeting.
Elevated PSA Link to Higher Recurrence Risk in Intermediate-Risk Prostate Cancer
Among those with intermediate-risk prostate cancer, high PSA levels prior to HIFU led to an increased risk of overall recurrence and treatment failure.
Facing Cancer Together: Jim and Melanie’s Patient-Caregiver Story
Diagnosed with stage 3B lung cancer in 2018, I joined a support group where I met Jim and Melanie, and learned about Jim's sarcoma diagnosis.
Breyanzi Improves Responses in R/R Indolent B-Cell Non-Hodgkin Lymphoma
Breyanzi has shown significant efficacy and durable responses in patients with marginal zone lymphoma.
Talzenna Plus Xtandi May Improve Survival in mCRPC
Patients with HRR-deficient metastatic castration-resistant prostate cancer experienced a 14-month gain in OS and a 38% lower death risk with Talzenna plus Xtandi.
Phase 2 Trial of Firi-Cel CAR T-Cell Therapy Discontinued in Lymphoma
The FIRCE-1 trial investigating the CAR T-cell therapy firi-cel in relapsed/refractory large B-cell lymphoma has been discontinued.
GI Bleeding Significantly Impacts GIST Treatment Outcomes
The prognosis of patients with gastrointestinal stromal tumors is significantly impacted by gastrointestinal bleeding.
Moving Slower and Slower After Myelodysplastic Syndrome
I have been frustrated lately by my increasing slowness following an blood cancer diagnosis, which has become noticeable to others.
Empowering Patients and Advocating For Yourself After Cervical Cancer
Dr. Ritu Salani discusses how patients with cervical cancer can advocate for their health and collaborate with their medical team to ensure the best care.
FDA Approves Adcetris With Revlimid and Rituxan For R/R LBCL
The FDA has approved Adcetris plus Revlimid and Rituxan in adults with relapsed or refractory large B-cell lymphoma.
An Expert Explains the Enhertu Approval in HER2-Low and -Ultralow Breast Cancer
Dr. Debu Tripathy discusses the FDA approval of Enhertu in unresectable or metastatic hormone receptor HR+, HER2-low or -ultralow breast cancer.
Test May Predict Likelihood of Bladder Cancer Upstaging
The Decipher Bladder Genomic Subtyping Classifier found that patients with luminal tumors may have less aggressive disease.
Breaking Down The Importance of Targeted Therapies in Colorectal Cancer Care
Dr. Suneel Kamath discusses the ALASCCA study in colorectal cancer and highlighted the importance of next-generation sequencing and testing.
Unexpected Support in Tough Times With Multiple Myeloma
Throughout my experience with multiple myeloma, I was humbled by the unexpected support and kindness shown to me.
